News | January 03, 2011

FDA Accepts Cervical Cancer Scanner PMA Application

January 3, 2011 — Guided Therapeutics Inc. announced that it was notified by the U.S. Food and Drug Administration (FDA) that the company’s premarket approval application (PMA) for the LightTouch cervical scanner, for patients at risk for cervical cancer, is “suitable for filing.”

The FDA notification said that FDA will schedule the Obstetrics and Gynecology Devices Panel meeting to review the PMA at a date to be determined.

The chance for successful treatment of cervical cancer is greatly increased by early detection, according to the National Cancer Institute. Each year about 55 million Pap (Papanicolau) tests are performed in the United States to detect cervical abnormalities that could lead to cancer. Of these tests, approximately six percent are abnormal, requiring additional medical evaluation, such as a biopsy. However, the majority of biopsies reveal no cervical disease, meaning that a significant number of potentially avoidable procedures are performed every year.

In the pivotal trial to support the PMA filing, more than 1,600 women at risk for cervical disease were tested with the LightTouch. Results of the trial showed that:

• LightTouch detected cervical disease up to two years earlier than Pap test, HPV (human papillomavirus) test, colposcopy and biopsy.
• LightTouch detected 86.3 percent of cervical disease cases that had been missed by Pap, HPV tests and biopsy.
• LightTouch would have reduced the number of avoidable biopsies by about 40 percent.

Additionally, the clinical trial indicated that women aged 16-20 were just as likely to have cervical disease as women 21 and older, and current methods of early detection, such as HPV testing, are not recommended for this age group. LightTouch detected cervical disease equally well in both adolescent and adult women.

The LightTouch scans the cervix with light to identify cancer and pre-cancer painlessly and noninvasively. Its patented biophotonic technology is able to distinguish between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the LightTouch test does not require laboratory analysis or a tissue sample, is designed to provide results immediately and eliminate costly unnecessary testing.

For more information:

Related Content

Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Imaging | January 17, 2018
January 17, 2018 — Philips recently announced the launch of Technology Maximizer, a cross-modality program designed t
RSNA 2017 Celebrates Innovation in Radiology
News | Imaging | January 15, 2018
January 15, 2018 — The Radiological Society of North America’s...
Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Fat Distribution in Women and Men Provides Clues to Heart Attack Risk
News | Women's Health | January 11, 2018
January 11, 2018 – It’s not the amount of fat in your body but where it is stored that may increase your risk for hea

Size comparison between 3-D printed prosthesis implant and a penny.

News | 3-D Printing | January 11, 2018
January 11, 2018 — Researchers using...
RSNA 2017 technical exhibits, expo floor, showing new radiology technology advances.
Feature | RSNA 2017 | January 11, 2018
January 11, 2018 — Here is a list of some of the key clinical study presentations, articles on trends and videos from
The artificial intelligence (AI) smart algorithm onboard the Infervision stroke product calculates the volume of bleed on the basis of multiple brain CT slices.

The AI smart algorithm onboard the Infervision stroke product calculates the volume of bleed on the basis of multiple brain CT slices. The size of the bleed volume indicates the urgency and type of treatment required.

Feature | Artificial Intelligence | January 10, 2018 | Greg Freiherr
Exhibitors at the 2017 Radiological Society of North American (RSNA) meeting rode the...
Women Prefer Getting Mammograms Every Year
News | Mammography | January 09, 2018
Women prefer to get their mammograms every year, instead of every two years, according to a new study presented at the...
Upcoming radiology conferences, meetings and events. This photo is from the 2017 RSNA opening session.
News | January 09, 2018
ITN maintains a comprehensive listing of radiology specialty meetings on its website at ...
Planmed Clarity 2-D Digital Mammography System Receives FDA Approval
Technology | Mammography | January 08, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the Planmed Clarity 2-D full-field digital...
Overlay Init